Sign in Subscribe
Pharmaceutical industry

Strategic Alliances Drive Breast Cancer Therapeutics Market

Strategic Insights

— 1 min read

Strategic alliances between the pharmaceutical industry and biotechnology sector are set to drive revenue growth in the breast cancer therapeutic market. These partnerships are producing novel, targeted biologics that promise an advance over existing chemotherapy and hormonal treatments. Analysts at Frost & Sullivan predict that a strong pipeline of pioneering therapeutics, including small molecules, monoclonal antibodies, and gene therapy, will significantly impact the market.

Key Takeaways:

  • Strategic alliances between pharmaceutical and biotechnology companies are creating novel, targeted biologics for breast cancer treatment.
  • Adjuvant therapy settings have more revenue potential due to longer treatment periods and potential to cure the disease.
  • Aventis' Taxotere and Roche's Xeloda are expected to be key growth drivers in the cytotoxic market.
  • Novel chemopotentiators, such as YM BioSciences' tesmilifene, are set to revolutionize chemotherapy treatment regimens.
  • Aromatase inhibitors, such as Pfizer's Aromasin, AstraZeneca's Arimidex, and Novartis' Femara, are expected to energize market growth with their increased efficacy and decreased side-effect profile.
  • Biologics, such as Roche's Herceptin, are expected to power the biological market with their likely use in adjuvant settings.

Statistics:

  • The breast cancer therapeutic market is expected to be driven by a strong pipeline of pioneering therapeutics, including small molecules, monoclonal antibodies, and gene therapy.
  • Adjuvant therapy settings are expected to have a longer treatment period, with patients on therapy for up to 2 years.
  • Pfizer's Aromasin, AstraZeneca's Arimidex, and Novartis' Femara are expected to be used in adjuvant, neo-adjuvant, and extended adjuvant therapeutic settings for post-menopausal women.
  • Roche's Herceptin is expected to power the biological market with its likely use in adjuvant settings for women with HER2-positive early-stage breast cancer.
  • Genentech's Avastin is currently undergoing clinical evaluation for the treatment of metastatic breast cancer.

Sources:

  • [1] Frost & Sullivan, "Strategic Analysis of the Global Breast Cancer Therapeutic Pipeline" (no date provided)
  • [2] Marketletter, "Pfizer's Aromasin wins FDA approval" (September 11, 1999)
  • [3] Marketletter, "AstraZeneca's Arimidex cleared by FDA for early breast cancer" (September 16, 2002)
  • [4] Marketletter, "Novartis' Femara cleared by FDA for advanced cancer in post-menopausal women" (no date provided)

Read more